SUBSTITUTED PHENYL PHENOL LEUKOTRIENE ANTAGONISTS
ANTAGONISTS HAVING A SUBSTITUTED PHENYL PHENOL OR A SUBSTITUTED PHENOLIC BIPHENYL STRUCTURE, AND VARIOUS DERIVATIVES THEREOF, ARE SPECIFIC LEUKOTRIENE ANTAGONISTS. THEIR STRUCTURES, USE AND SYNTHESIS ARE DISCLOSED. ALSO, PHARMACEUTICAL FORMULATIONS ARE DISCLOSED FOR USE IN APPLICATIONS TREATING DISE...
Gespeichert in:
| Hauptverfasser: | , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | PAUL EDWARD FLOREANCIG ELISABETH ANDREE SCHMITTLING ROBERT DELANE DILLARD STEPHEN RICHARD BAKER MICHAEL JOSEPH SOFIA JASON SCOTT SAWYER |
| description | ANTAGONISTS HAVING A SUBSTITUTED PHENYL PHENOL OR A SUBSTITUTED PHENOLIC BIPHENYL STRUCTURE, AND VARIOUS DERIVATIVES THEREOF, ARE SPECIFIC LEUKOTRIENE ANTAGONISTS. THEIR STRUCTURES, USE AND SYNTHESIS ARE DISCLOSED. ALSO, PHARMACEUTICAL FORMULATIONS ARE DISCLOSED FOR USE IN APPLICATIONS TREATING DISEASES OR CONDITIONS CHARACTERIZED BY EXCESSIVE RELEASE OF LEUKOTRIENE B4, ONE OF THE METABOLITES OF ARACHIDONIC ACID. THE PRIMARY LTB4 ANTAGONISTIC STRUCTURES ARE REPRESENTED AS: WHEREIN RL, R2, R3, R41 X, Y, Z, AND A ARE DESCRIBED IN DETAIL IN THIS APPLICATION. THIS INVENTION ALSO PROVIDES A PROCESS FOR PREPARING INTERMEDIATE COMPOUNDS OF THE FORMULA XI: WHEREIN R21, R22, AND R23 AND T ARE AS DESCRIBED IN THIS APPLICATION. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_MY141472A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>MY141472A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_MY141472A3</originalsourceid><addsrcrecordid>eNrjZDAMDnUKDvEMCQ1xdVEI8HD1i_QBU_4-Cj6uod7-IUGern6uCo5-IY7u_n6ewSHBPAysaYk5xam8UJqbQc7NNcTZQze1ID8-tbggMTk1L7Uk3jfS0MTQxNzI0ZigAgC6JSYK</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>SUBSTITUTED PHENYL PHENOL LEUKOTRIENE ANTAGONISTS</title><source>esp@cenet</source><creator>PAUL EDWARD FLOREANCIG ; ELISABETH ANDREE SCHMITTLING ; ROBERT DELANE DILLARD ; STEPHEN RICHARD BAKER ; MICHAEL JOSEPH SOFIA ; JASON SCOTT SAWYER</creator><creatorcontrib>PAUL EDWARD FLOREANCIG ; ELISABETH ANDREE SCHMITTLING ; ROBERT DELANE DILLARD ; STEPHEN RICHARD BAKER ; MICHAEL JOSEPH SOFIA ; JASON SCOTT SAWYER</creatorcontrib><description>ANTAGONISTS HAVING A SUBSTITUTED PHENYL PHENOL OR A SUBSTITUTED PHENOLIC BIPHENYL STRUCTURE, AND VARIOUS DERIVATIVES THEREOF, ARE SPECIFIC LEUKOTRIENE ANTAGONISTS. THEIR STRUCTURES, USE AND SYNTHESIS ARE DISCLOSED. ALSO, PHARMACEUTICAL FORMULATIONS ARE DISCLOSED FOR USE IN APPLICATIONS TREATING DISEASES OR CONDITIONS CHARACTERIZED BY EXCESSIVE RELEASE OF LEUKOTRIENE B4, ONE OF THE METABOLITES OF ARACHIDONIC ACID. THE PRIMARY LTB4 ANTAGONISTIC STRUCTURES ARE REPRESENTED AS: WHEREIN RL, R2, R3, R41 X, Y, Z, AND A ARE DESCRIBED IN DETAIL IN THIS APPLICATION. THIS INVENTION ALSO PROVIDES A PROCESS FOR PREPARING INTERMEDIATE COMPOUNDS OF THE FORMULA XI: WHEREIN R21, R22, AND R23 AND T ARE AS DESCRIBED IN THIS APPLICATION.</description><language>eng</language><subject>ACYCLIC OR CARBOCYCLIC COMPOUNDS ; CHEMISTRY ; HETEROCYCLIC COMPOUNDS ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2010</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20100430&DB=EPODOC&CC=MY&NR=141472A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20100430&DB=EPODOC&CC=MY&NR=141472A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>PAUL EDWARD FLOREANCIG</creatorcontrib><creatorcontrib>ELISABETH ANDREE SCHMITTLING</creatorcontrib><creatorcontrib>ROBERT DELANE DILLARD</creatorcontrib><creatorcontrib>STEPHEN RICHARD BAKER</creatorcontrib><creatorcontrib>MICHAEL JOSEPH SOFIA</creatorcontrib><creatorcontrib>JASON SCOTT SAWYER</creatorcontrib><title>SUBSTITUTED PHENYL PHENOL LEUKOTRIENE ANTAGONISTS</title><description>ANTAGONISTS HAVING A SUBSTITUTED PHENYL PHENOL OR A SUBSTITUTED PHENOLIC BIPHENYL STRUCTURE, AND VARIOUS DERIVATIVES THEREOF, ARE SPECIFIC LEUKOTRIENE ANTAGONISTS. THEIR STRUCTURES, USE AND SYNTHESIS ARE DISCLOSED. ALSO, PHARMACEUTICAL FORMULATIONS ARE DISCLOSED FOR USE IN APPLICATIONS TREATING DISEASES OR CONDITIONS CHARACTERIZED BY EXCESSIVE RELEASE OF LEUKOTRIENE B4, ONE OF THE METABOLITES OF ARACHIDONIC ACID. THE PRIMARY LTB4 ANTAGONISTIC STRUCTURES ARE REPRESENTED AS: WHEREIN RL, R2, R3, R41 X, Y, Z, AND A ARE DESCRIBED IN DETAIL IN THIS APPLICATION. THIS INVENTION ALSO PROVIDES A PROCESS FOR PREPARING INTERMEDIATE COMPOUNDS OF THE FORMULA XI: WHEREIN R21, R22, AND R23 AND T ARE AS DESCRIBED IN THIS APPLICATION.</description><subject>ACYCLIC OR CARBOCYCLIC COMPOUNDS</subject><subject>CHEMISTRY</subject><subject>HETEROCYCLIC COMPOUNDS</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2010</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZDAMDnUKDvEMCQ1xdVEI8HD1i_QBU_4-Cj6uod7-IUGern6uCo5-IY7u_n6ewSHBPAysaYk5xam8UJqbQc7NNcTZQze1ID8-tbggMTk1L7Uk3jfS0MTQxNzI0ZigAgC6JSYK</recordid><startdate>20100430</startdate><enddate>20100430</enddate><creator>PAUL EDWARD FLOREANCIG</creator><creator>ELISABETH ANDREE SCHMITTLING</creator><creator>ROBERT DELANE DILLARD</creator><creator>STEPHEN RICHARD BAKER</creator><creator>MICHAEL JOSEPH SOFIA</creator><creator>JASON SCOTT SAWYER</creator><scope>EVB</scope></search><sort><creationdate>20100430</creationdate><title>SUBSTITUTED PHENYL PHENOL LEUKOTRIENE ANTAGONISTS</title><author>PAUL EDWARD FLOREANCIG ; ELISABETH ANDREE SCHMITTLING ; ROBERT DELANE DILLARD ; STEPHEN RICHARD BAKER ; MICHAEL JOSEPH SOFIA ; JASON SCOTT SAWYER</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_MY141472A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2010</creationdate><topic>ACYCLIC OR CARBOCYCLIC COMPOUNDS</topic><topic>CHEMISTRY</topic><topic>HETEROCYCLIC COMPOUNDS</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>PAUL EDWARD FLOREANCIG</creatorcontrib><creatorcontrib>ELISABETH ANDREE SCHMITTLING</creatorcontrib><creatorcontrib>ROBERT DELANE DILLARD</creatorcontrib><creatorcontrib>STEPHEN RICHARD BAKER</creatorcontrib><creatorcontrib>MICHAEL JOSEPH SOFIA</creatorcontrib><creatorcontrib>JASON SCOTT SAWYER</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>PAUL EDWARD FLOREANCIG</au><au>ELISABETH ANDREE SCHMITTLING</au><au>ROBERT DELANE DILLARD</au><au>STEPHEN RICHARD BAKER</au><au>MICHAEL JOSEPH SOFIA</au><au>JASON SCOTT SAWYER</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>SUBSTITUTED PHENYL PHENOL LEUKOTRIENE ANTAGONISTS</title><date>2010-04-30</date><risdate>2010</risdate><abstract>ANTAGONISTS HAVING A SUBSTITUTED PHENYL PHENOL OR A SUBSTITUTED PHENOLIC BIPHENYL STRUCTURE, AND VARIOUS DERIVATIVES THEREOF, ARE SPECIFIC LEUKOTRIENE ANTAGONISTS. THEIR STRUCTURES, USE AND SYNTHESIS ARE DISCLOSED. ALSO, PHARMACEUTICAL FORMULATIONS ARE DISCLOSED FOR USE IN APPLICATIONS TREATING DISEASES OR CONDITIONS CHARACTERIZED BY EXCESSIVE RELEASE OF LEUKOTRIENE B4, ONE OF THE METABOLITES OF ARACHIDONIC ACID. THE PRIMARY LTB4 ANTAGONISTIC STRUCTURES ARE REPRESENTED AS: WHEREIN RL, R2, R3, R41 X, Y, Z, AND A ARE DESCRIBED IN DETAIL IN THIS APPLICATION. THIS INVENTION ALSO PROVIDES A PROCESS FOR PREPARING INTERMEDIATE COMPOUNDS OF THE FORMULA XI: WHEREIN R21, R22, AND R23 AND T ARE AS DESCRIBED IN THIS APPLICATION.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng |
| recordid | cdi_epo_espacenet_MY141472A |
| source | esp@cenet |
| subjects | ACYCLIC OR CARBOCYCLIC COMPOUNDS CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | SUBSTITUTED PHENYL PHENOL LEUKOTRIENE ANTAGONISTS |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T04%3A12%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=PAUL%20EDWARD%20FLOREANCIG&rft.date=2010-04-30&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EMY141472A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |